fenfluramine

"1-Phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension." []

fenfluramine

Beilstein:2109374 "Beilstein Registry Number", ChemIDplus:458-24-2 "CAS Registry Number", DrugBank:DB00574 "DrugBank", KEGG COMPOUND:458-24-2 "CAS Registry Number", KEGG COMPOUND:C06996 "KEGG COMPOUND", KEGG DRUG:D07945 "KEGG DRUG", NIST Chemistry WebBook:458-24-2 "CAS Registry Number", Patent:US3198833 "Patent"

fenfluramine, (+-)-fenfluramine, 3-(trifluoromethyl)-N-ethyl-alpha-methylphenethylamine, 2-ethylamino-1-(3-trifluoromethylphenyl)propane, 1-(m-trifluoromethyl-phenyl)-2-ethylaminopropane, fenfluraminum, N-ethyl-alpha-methyl-3-trifluoromethylphenethylamine, N-ethyl-1-(3-(trifluoromethyl)phenyl)propan-2-amine, Ethyl-[1-methyl-2-(3-trifluoromethyl-phenyl)-ethyl]-amine, C12H16F3N, CCNC(C)Cc1cccc(c1)C(F)(F)F, InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3, InChIKey=DBGIVFWFUFKIQN-UHFFFAOYSA-N